PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer

Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?

(2018) Conor E. Steuer et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report

(2018) Yuki Owada-Ozaki et al.   Journal of Thoracic Oncology

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67

(2018) Junnan Xu et al.   OncoTargets and Therapy

The landscape of somatic mutation in sporadic Chinese colorectal cancer

(2018) Zhe Liu et al.   Oncotarget

Functionalized rare earth-doped nanoparticles for breast cancer nanodiagnostic using fluorescence and CT imaging

(2018) Akhil Jain et al.   JOURNAL OF NANOBIOTECHNOLOGY

Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer

(2018) Xiangchun Li et al.   JAMA Oncology

Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis

(2017) Yingying Chen et al.   HUMAN PATHOLOGY

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transcriptional landscape of human cancers

(2017) Mengyuan Li et al.   Oncotarget

Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors

(2016) Jaegil Kim et al.   NATURE GENETICS

NTN4 is associated with breast cancer metastasis via regulation of EMT-related biomarkers

(2016) Xiuping Xu et al.   ONCOLOGY REPORTS

A Novel Mutant Allele of Pw1/Peg3 Does Not Affect Maternal Behavior or Nursing Behavior

(2016) Anne-Lyse Denizot et al.   PLoS Genetics

Immunotherapy for the Treatment of Breast Cancer

(2015) Brenda Ernst et al.   Current Oncology Reports

Breast cancer statistics, 2013

(2013) Carol DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Associations between Methylation of Paternally Expressed Gene 3 (PEG3), Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer

(2013) Monica D. Nye et al.   PLoS One

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations

(2013) Nicolai Juul Birkbak et al.   PLoS One

p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer

(2012) James G. Jackson et al.   CANCER CELL

Exome sequencing of liver fluke–associated cholangiocarcinoma

(2012) Choon Kiat Ong et al.   NATURE GENETICS

The Imprinted GenePEG3Inhibits Wnt Signaling and Regulates Glioma Growth

(2010) Xiuli Jiang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Accumulation of driver and passenger mutations during tumor progression

(2010) I. Bozic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aberrant promoter methylation and expression of the imprinted PEG3 gene in glioma

(2009) Susumu OTSUKA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Imprinted tumor suppressor genesARHI andPEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation

(2008) Weiwei Feng et al.   CANCER